ANAB
ANAB
NASDAQ · Biotechnology

Anaptysbio Inc

$45.58
-1.93 (-4.06%)
As of Nov 7, 1:51 AM ET ·
Financial Highlights (FY 2026)
Revenue
42.63M
Net Income
105.28M
Gross Margin
—
Profit Margin
247.0%
Rev Growth
+45.7%
D/E Ratio
24.23
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 67.0% 67.0%
Operating Margin 60.9% 54.8% 1.0% 1.3%
Profit Margin 247.0% 234.6% 1.1% 1.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 42.63M 29.26M 183.45M 146.61M
Gross Profit — — 122.96M 98.26M
Operating Income 25.97M 16.05M 1.91M 1.85M
Net Income 105.28M 65.04M 2.09M 1.41M
Gross Margin — — 67.0% 67.0%
Operating Margin 60.9% 54.8% 1.0% 1.3%
Profit Margin 247.0% 234.6% 1.1% 1.0%
Rev Growth +45.7% +45.7% +5.3% +16.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 659.19M 659.19M 219.73M 209.35M
Total Equity 27.20M 27.20M 894.48M 927.05M
D/E Ratio 24.23 24.23 0.25 0.23
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 25.98M 16.94M 3.06M 2.67M
Free Cash Flow — — 1.04M 763.9K